Results 81 to 90 of about 154,650 (346)

Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial

open access: yesAlimentary Pharmacology and Therapeutics
Semaglutide, a glucagon‐like peptide‐1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction‐associated steatohepatitis (MASH).
Philip N. Newsome   +9 more
semanticscholar   +1 more source

Rab1A Promotes Hepatic Steatosis by Suppressing Mitophagy via the Raf‐1/ERK1/2/PINK1 Signaling Axis

open access: yesAdvanced Science, EarlyView.
Why does fat accumulate in the liver? Our study reveals Rab1A as the molecular switch that silences the cell's mitochondrial cleanup crew. Turning Rab1A off reactivates mitophagy, clears excess fat, and reverses fatty liver disease in mice—offering a promising new therapeutic target for MASLD, a growing global health challenge.
Li Zhang   +9 more
wiley   +1 more source

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

open access: yesHepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo   +19 more
wiley   +1 more source

Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.

open access: yesJournal of Hepatology, 2022
BACKGROUND & AIMS Non-alcoholic steatohepatitis (NASH) is associated with the dysregulation of lipid metabolism and hepatic inflammation. The mechanism underlying NASH is unclear.
Qi Wang   +11 more
semanticscholar   +1 more source

Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe? [PDF]

open access: yes, 2018
Nonalcoholic steatohepatitis (NASH) is a subtype of nonalcoholic fatty liver disease that is characterised by steatosis, chronic inflammation, and hepatocellular injury with or without fibrosis.
Inderdeep Gakhal   +5 more
core  

IMAGING DIAGNOSIS OF NONALCOHOLIC STEATOHEPATITIS [PDF]

open access: yes, 2018
Non-alcoholic fatty liver comprises several clinical entities, starting from hepatic steatosis and reaching steatohepatitis, fibrosis and liver cirrhosis; it is currently considered a major public health issue.
Gabriel Nicolae Ianosi   +6 more
core   +2 more sources

An Adipocyte MKK3–p38β Axis Preserves Insulin Responsiveness in Mice and Is Reciprocally Altered in Human Obesity

open access: yesAdvanced Science, EarlyView.
The adipocyte MKK3–p38β axis emerges as an adaptive stress‐response pathway during obesity. Human visceral adipose tissue analyses, adipocyte‐specific mouse models, and primary adipocytes show that the MKK3–p38β axis supports insulin responsiveness by restraining p70S6K‐dependent inhibitory IRS1 feedback and preserving AKT–GLUT4 signaling. This pathway
Edgar Bernardo   +20 more
wiley   +1 more source

Noninvasive tests for nonalcoholic fatty liver disease in a multi‐ethnic population: The HELIUS study

open access: yesHepatology Communications, EarlyView., 2022
Abstract Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence and severity globally, prompting noninvasive testing, yet limited data exist on noninvasive liver tests (NITs) including transient elastography (TE) in ethnically diverse populations.
Anne‐Marieke van Dijk   +6 more
wiley   +1 more source

Emerging Insights into the Role of BDNF on Health and Disease in Periphery

open access: yesBiomolecules
Brain-derived neurotrophic factor (BDNF) is a growth factor that promotes the survival and growth of developing neurons. It also enhances circuit formation to synaptic transmission for mature neurons in the brain.
Mayuko Ichimura-Shimizu   +5 more
doaj   +1 more source

A new non-invasive method for assessing steatosis in chronic liver diseases [PDF]

open access: yesТерапевтический архив, 2016
Aim. To assess the diagnostic accuracy of the controlled attenuation parameter (CAP) to determine the grade of hepatic steatosis (HS) in patients with chronic liver diseases (CLD) of different etiologies and to compare the obtained results with ...
I G Bakulin   +3 more
doaj  

Home - About - Disclaimer - Privacy